Literature DB >> 15519620

Should rosuvastatin be withdrawn from the market?

John J P Kastelein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15519620     DOI： 10.1016/S0140-6736(04)17302-9

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

1.  Safety profile of rosuvastatin: results of a prescription-event monitoring study of 11,680 patients.

Authors:  Rachna Kasliwal; Lynda V Wilton; Victoria Cornelius; Beate Aurich-Barrera; Saad A W Shakir
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

2.  Association of Rosuvastatin Use with Risk of Hematuria and Proteinuria.

Authors:  Jung-Im Shin; Derek M Fine; Yingying Sang; Aditya Surapaneni; Stephan C Dunning; Lesley A Inker; Thomas D Nolin; Alex R Chang; Morgan E Grams
Journal:  J Am Soc Nephrol       Date:  2022-07-19       Impact factor: 14.978

3.  Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system.

Authors:  Toshiyuki Sakaeda; Kaori Kadoyama; Yasushi Okuno
Journal:  PLoS One       Date:  2011-12-20       Impact factor: 3.240

4.  Evidence-based prescribing of statins: a developing world perspective.

Authors:  H T Ong
Journal:  PLoS Med       Date:  2006-02-21       Impact factor: 11.069
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.